BiotechTube

Datopotamab Deruxtecan (Dato-DXd)

Phase 1/2Active
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoma, Non-Small-Cell Lung

Conditions

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer

Trial Timeline

Jul 11, 2022 → Jun 30, 2026

NCT ID
NCT05460273

About Datopotamab Deruxtecan (Dato-DXd)

Datopotamab Deruxtecan (Dato-DXd) is a phase 1/2 stage product being developed by Daiichi Sankyo for Carcinoma, Non-Small-Cell Lung. The current trial status is active. This product is registered under clinical trial identifier NCT05460273. Target conditions include Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05460273Phase 1/2Active

Competing Products

20 competing products in Carcinoma, Non-Small-Cell Lung

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
28
Cemiplimab + CetuximabEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
25
BB-401Benitec BiopharmaPhase 2
44
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
AzenosertibZentalis PharmaceuticalsPhase 2
44
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
25
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
Ramucirumab + PaclitaxelEli LillyPhase 2
52
LY2875358 + ErlotinibEli LillyPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85